Ophthalmic Diseases Archives · BioBuzz

Translational Potential of hMSCs for Ocular Diseases

<img width="300" height="300" src="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2022/08/SocialPost-August-webinar-300x300.jpg?lossy=1&strip=1&webp=1" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image" alt="" decoding="async" srcset="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2022/08/SocialPost-August-webinar-75x75.jpg?lossy=1&strip=1&webp=1 75w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2022/08/SocialPost-August-webinar-150x150.jpg?lossy=1&strip=1&webp=1 150w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2022/08/SocialPost-August-webinar.jpg?size=240x240&lossy=1&strip=1&webp=1 240w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2022/08/SocialPost-August-webinar-300x300.jpg?lossy=1&strip=1&webp=1 300w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : August 10, 2022August 10, 2022 Published by : Chris Frew

Join RoosterBio on Tuesday, August 23rd at 1:00 PM EST for our latest webinar: Translational Potential of hMSCs for Ocular Diseases. This seminar will be presented by Dr. Ali Djalilian, [….]

Adaptive Phage Therapeutics Announces Collaboration with Oyster Point Pharma to Target Ophthalmic Diseases

<img width="300" height="300" src="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/New_APT_Logo_-_03.09.21-300x300.jpg?lossy=1&strip=1&webp=1" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/New_APT_Logo_-_03.09.21-75x75.jpg?lossy=1&strip=1&webp=1 75w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/New_APT_Logo_-_03.09.21-150x150.jpg?lossy=1&strip=1&webp=1 150w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/New_APT_Logo_-_03.09.21.jpg?size=240x240&lossy=1&strip=1&webp=1 240w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/05/New_APT_Logo_-_03.09.21-300x300.jpg?lossy=1&strip=1&webp=1 300w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : June 10, 2021June 10, 2021 Published by : BioBuzz Media

Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced a newly-formed research collaboration with Oyster Point Pharma, Inc. (Nasdaq: OYST) for developing therapies, using APT’s PhageBank™ technology, potentially targeting multiple ophthalmic diseases.